10-K: Kaya Holdings Eyes Psychedelic Market with Flagship Treatment Center, Reports Mixed Financial Results

Kaya Holdings is transitioning towards psychedelic therapeutics with the planned opening of 'The Sacred Mushroom' treatment center, while reporting a net income for 2023 primarily due to derivative liability adjustments.

Summary

• Kaya Holdings, Inc. is shifting its focus from cannabis to psychedelic treatments, planning to open 'The Sacred Mushroom' in Portland, Oregon.
• The company aims to be the first US public company to operate a licensed psychedelic treatment facility.
• Kaya Holdings reported a net income of $1,609,697 for 2023, a significant turnaround from a net loss of $3,576,614 in 2022, primarily due to changes in derivative liabilities.
• Revenue decreased from $685,379 in 2022 to $196,294 in 2023 due to the closure of a retail shop in Oregon.
• The company sold a 26-acre property in Lebanon, Oregon for $769,500 and a retail cannabis store in Salem for $210,000, netting approximately $420,000 for working capital.
• Kaya Holdings is also exploring international cannabis opportunities, particularly in Greece, with existing cultivation and processing projects.
• The global psychedelic therapeutics market is estimated to reach $8.31 billion by 2028, with a CAGR of 13.2%.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company is making progress in the psychedelic market and has achieved a net income for 2023, it faces significant financial challenges, including a working capital deficiency and reliance on additional financing. The shift in focus to psychedelics is a positive move, but the company's past performance and current financial situation temper the overall sentiment.

Positives

• The company is positioned to be a first mover in the emerging US psychedelic therapeutics industry.
• The company has secured over $700,000 in institutional investment for its psychedelic therapeutics venture.
• The company has a certified psilocybin facilitator on staff.
• The company has a strong understanding of Oregon regulations due to its history in the cannabis industry.
• The company has a significant genetic library of cannabis seeds for future international grow operations.
• The company has a net income of $1,609,697 for 2023, a significant turnaround from a net loss of $3,576,614 in 2022.

Negatives

• The company's revenue decreased significantly from $685,379 in 2022 to $196,294 in 2023.
• The company has a working capital deficiency of $7,307,979 as of December 31, 2023.
• The company relies on key individuals, and their loss could adversely affect the company.
• The company's internal controls over financial reporting are not effective.
• The company's common stock is a penny stock, which may limit trading activity.
• The company has a history of losses and may not achieve profitability.

Risks

• The company has a limited operating history with its current businesses.
• The company will require additional financing to become commercially viable.
• The company's success depends on key individuals, and their loss could have an adverse effect.
• Marijuana and psilocybin remain illegal under federal law in the United States.
• The marketing and market acceptance of marijuana and psilocybin may not be as rapid as expected.
• The company faces significant competition in both the cannabis and psychedelic sectors.
• The company's internal controls may be inadequate, which could cause financial reporting to be unreliable.
• The company's stock is a penny stock and is subject to penny stock regulations.
• The company's principal stockholders may control the business and limit minority stockholders' influence.
• The company does not expect to pay cash dividends in the foreseeable future.
• The company has a substantial amount of convertible debt that could cause dilution.

Future Outlook

The company plans to expand its psychedelic treatment centers to other states and international locations as regulations unfold, and intends to explore additional cannabis opportunities as new markets develop. The company is also seeking additional capital to fund its expansion.

Management Comments

• The company intends to explore additional cannabis opportunities as new markets develop.
• The company believes it could acquire either of the properties in Greece once funding and market conditions allow.
• The company is moving to first establish a Psychedelic Treatment Center in Oregon, but is also keeping abreast of developments in other states and international locations.

Industry Context

The company is capitalizing on the growing trend of legalizing and exploring the therapeutic potential of psychedelics, particularly psilocybin, while also navigating the evolving landscape of the cannabis industry. The company is positioning itself to be a leader in the delivery of psychedelic care, offering more immediate relief for people with pressing mental health conditions.

Comparison to Industry Standards

• The company is aiming to offer psilocybin treatments at a lower price point than competitors, with some facilities in Oregon charging up to $15,000 for a first-time full dose treatment.
• The company is competing with companies such as Compass Pathways, ATAI Life Sciences, and Cybin, which are developing synthetic versions of psilocybin.
• The company is leveraging its experience in the cannabis industry to navigate the regulatory landscape of the emerging psychedelic market, similar to how other companies are leveraging their experience in other industries to enter the psychedelic market.
• The company is aiming to be the first US public company to own and operate a US based licensed Psychedelic Treatment Facility, which would be a significant achievement in the industry.

Legal Proceedings

• The company was involved in a lawsuit with Day Law & Associates, P.C., which was resolved in the company's favor through arbitration.
• The company is currently involved in a lawsuit with P3 Distributing LLC for unpaid vendor invoices.

Related Party Transactions

• The company has consulting agreements with The Tudog Group and BMN Consultants, Inc., which are related parties.
• The company has a $250,000 non-convertible note payable to a related party.
• The company has a $500,000 non-convertible note payable to a related party.
• The company has a $250,000 non-convertible note payable to a related party.

Stakeholder Impact

• Shareholders may be impacted by the company's shift in focus and the potential for dilution from convertible debt.
• Employees may be impacted by the company's restructuring and expansion plans.
• Customers may benefit from the company's new psychedelic treatment offerings.
• Creditors may be impacted by the company's financial challenges and reliance on additional financing.
• Suppliers may be impacted by the company's shift in focus and potential changes in purchasing patterns.

Next Steps

• The company anticipates receiving its license for 'The Sacred Mushroom' within 30 days of the report date.
• The company plans to open 'The Sacred Mushroom' psychedelic treatment center in Portland, Oregon.
• The company intends to explore additional cannabis opportunities as new markets develop.
• The company will seek additional capital from further private offerings of equity and/or debt securities.
• The company will continue to monitor developments in other states and international locations for potential expansion of psychedelic treatment centers.

Key Dates

Keywords

psychedelic therapeutics, psilocybin, cannabis, mental health, treatment center, Oregon, Kaya Holdings, Fifth Dimension Therapeutics, The Sacred Mushroom, convertible debt